In this issue:
Bispecific antibody teclistamab shows encouraging efficacy in RRMM
NKG2D-CAR-transduced natural killer cells efficiently target MM
Promising preclinical results for novel BCMA-OR-CD38 tandem-dual CAR T cells
Does the presence of extramedullary disease impact the efficacy of anti-BCMA CAR T therapy?
KD-PACE salvage bridging therapy for aggressive subtypes of myeloma improves outcomes
Low-dose rivaroxaban thromboprophylaxis attenuates carfilzomib therapy-related risk of VTE
Selinexor suitable for early relapsed MM including patients with high-risk cytogenetics
MM patients mount a suboptimal humoral response to COVID vaccines
Chemotherapy-based stem cell mobilisation in MM patients who are poor responders to induction
Carfilzomib, bendamustine and dexamethasone for advanced MM
Please login below to download this issue (PDF)